ICCC

ImmuCell Corporation

ICCC, USA

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

https://immucell.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ICCC
stock
ICCC

Trading the Move, Not the Narrative: (ICCC) Edition news.stocktradersdaily.com

Read more →
ICCC
stock
ICCC

Breakouts Watch: Is BFA stock overvalued by current metrics - 2025 Pullback Review & Long-Term Investment Growth Plans moha.gov.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$14

Analyst Picks

Strong Buy

1

Buy

0

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Neutral

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Medium

28.81

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Medium

1.89

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-0.47 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-0.31 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-32.26 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

High

0.53

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 19.14% of the total shares of ImmuCell Corporation

1.

Vanguard Group Inc

(3.4126%)

since

2025/06/30

2.

Vanguard Total Stock Mkt Idx Inv

(2.0018%)

since

2025/07/31

3.

Renaissance Technologies Corp

(1.7686%)

since

2025/06/30

4.

Cresset Asset Management, LLC

(1.4592%)

since

2025/06/30

5.

Morgan Stanley - Brokerage Accounts

(1.1598%)

since

2025/06/30

6.

Bleichroeder LP

(1.1231%)

since

2025/06/30

7.

Dauntless Investment Group, LLC

(1.0468%)

since

2025/06/30

8.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9392%)

since

2025/07/31

9.

Geode Capital Management, LLC

(0.7943%)

since

2025/06/30

10.

Dimensional Fund Advisors, Inc.

(0.7733%)

since

2025/06/30

11.

Shufro Rose & CO LLC

(0.6747%)

since

2025/06/30

12.

Northern Trust Corp

(0.4701%)

since

2025/06/30

13.

Citadel Advisors Llc

(0.4527%)

since

2025/06/30

14.

Fidelity Extended Market Index

(0.3913%)

since

2025/07/31

15.

Strategic Investment Advisors Inc

(0.3427%)

since

2025/06/30

16.

HighTower Advisors, LLC

(0.2361%)

since

2025/06/30

17.

DFA US Core Equity 2 I

(0.2032%)

since

2025/07/31

18.

Prosperity Planning, Inc.

(0.1769%)

since

2025/06/30

19.

BlackRock Inc

(0.1746%)

since

2025/06/30

20.

DFA US Targeted Value I

(0.1707%)

since

2025/07/31

21.

iShares Micro-Cap ETF

(0.1543%)

since

2025/08/31

22.

Fidelity Total Market Index

(0.151%)

since

2025/07/31

23.

Mesirow Fin Investmt Mgmt Intl Equity

(0.1346%)

since

2025/06/30

24.

Dimensional US Targeted Value ETF

(0.1247%)

since

2025/08/29

25.

Essex Financial Services, Inc.

(0.1216%)

since

2025/06/30

26.

Fidelity Series Total Market Index

(0.1042%)

since

2025/07/31

27.

UBS Group AG

(0.0928%)

since

2025/06/30

28.

Spartan Extended Market Index Pool F

(0.0852%)

since

2025/07/31

29.

NT Ext Equity Mkt Idx Fd - NL

(0.0445%)

since

2025/06/30

30.

HM Payson & Co

(0.0442%)

since

2025/03/31

31.

NT Ext Equity Mkt Idx Fd - L

(0.0435%)

since

2025/06/30

32.

Northern Trust Extended Eq Market Idx

(0.0435%)

since

2025/06/30

33.

Spartan Total Market Index Pool G

(0.0415%)

since

2025/07/31

34.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0345%)

since

2025/06/30

35.

DFA US Vector Equity I

(0.0331%)

since

2025/07/31

36.

DFA US Core Equity Class F

(0.0267%)

since

2025/06/30

37.

DFA US Social Core Equity 2 Portfolio

(0.0233%)

since

2025/07/31

38.

Bank of America Corp

(0.0232%)

since

2025/06/30

39.

Fidelity Nasdaq Composite Index

(0.0222%)

since

2025/07/31

40.

Northern Small Cap Core I

(0.0217%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.02

EPS Estimate

—

EPS Difference

0

Surprise Percent

null%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(1.5)
Momentum
Strong Momentum(6.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(2)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.